Novo Nordisk ends $598m heart failure cell therapy deal with Heartseed
FierceBiotech - 30-Sep-2025Stem cell therapy for heart failure returns to Heartseed after Novo exits
Previously the Live Forever Club — same community, now with a sharper mission for life extension
Writer for Fierce Pharma
Zoey Becker is a staff writer at Fierce Pharma, having joined the team in 2022 following an internship at the Cincinnati Herald. She holds a degree in journalism and sociology from Miami University. Zoey currently lives in Chicago with her two goldfish.
Visit website: https://www.fiercebiotech.com/person/zoey-becker
See also
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company.
Details last updated 14-Feb-2025
Stem cell therapy for heart failure returns to Heartseed after Novo exits
Unity exits eye drug race, Mammoth tightens focus on CRISPR pipeline
The biotech’s advanced AI platform aims to unlock new treatments for challenging drug targets